moclobemide has been researched along with Depression in 36 studies
Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.
moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.
Depression: Depressive states usually of moderate intensity in contrast with MAJOR DEPRESSIVE DISORDER present in neurotic and psychotic disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this double-blind randomized study was to compare the efficacy and the tolerability of moclobemide (300-600 mg daily) and pirlindole (150-300 mg daily), two reversible inhibitors of MAO-A (RIMAs), in the treatment of depression." | 9.08 | Double-blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase A inhibitors, pirlindole and moclobemide, in the treatment of depression. ( Brichard, B; Bruhwyler, J; Géczy, J; Geerts, S; Tanghe, A; Van Dorpe, J, 1997) |
| "The efficiency of moclobemide (selective reversible inhibitor of monoamine oxidase) in therapy of "hyperestetic" depressions and the relation of the drug's efficiency with both psychopathologic structure and severity of the disease were assessed." | 7.70 | [Effectiveness of moclobemide in therapy-resistant depression]. ( Andriushchenko, AV; Kolesnikov, DB, 1998) |
| "Eighteen patients with refractory depression (dysthymia with superimposed major depression) were treated with a combination of fluvoxamine and moclobemide for 6 weeks and compared with 18 patients treated with fluvoxamine only." | 5.08 | Combined SSRI-RIMA treatment in refractory depression. Safety data and efficacy. ( Albert, R; Ebert, D; Kaschka, W; May, A; Stosiek, I, 1995) |
| " Does this mean that the SSRIs, moclobemide and mianserin should be the treatment of first choice for depression? On balance, the evidence presented in this article would suggest rather that the new agents and TCAs should all be considered first-line agents." | 4.79 | The management of depression. Part 2. The place of the new antidepressants. ( Mitchell, MS; Mitchell, PB, 1994) |
| " While clinical aspects will be presented in a subsequent review, this article focuses primarily on moclobemide's evolution, pharmacodynamic and pharmacokinetic properties." | 2.41 | Moclobemide: evolution, pharmacodynamic, and pharmacokinetic properties. ( Bonnet, U, 2002) |
| "Moclobemide is an effective and well-tolerated antidepressant for the treatment of elderly depressed patients." | 2.40 | Efficacy and tolerability of moclobemide in comparison with placebo, tricyclic antidepressants, and selective serotonin reuptake inhibitors in elderly depressed patients: a clinical overview. ( Affolter, E; Amrein, R; Henauer, S; Jonkanski, I; Stabl, M, 1997) |
| "Depression is a highly prevalent concomitant of dementia." | 2.40 | Depression and dementia: comorbidities, identification, and treatment. ( Meyers, BS, 1998) |
| " Mianserin and mirtazapine (separately) induced dose-dependent antinociception, each one yielding a biphasic dose-response curve, and they were antagonized by naloxone." | 1.91 | Treatment-Resistant Depression (TRD): Is the Opioid System Involved? ( Keidan, L; Pick, CG; Schreiber, S, 2023) |
| " Correlations between the single concentration-time points and the area under the concentration-time curve within a 6-hour dosing interval at steady-state (AUC(0-6)) were assessed by linear regression analyses." | 1.37 | Evaluation of single-point sampling strategies for the estimation of moclobemide exposure in depressive patients. ( Ignjatovic, AR; Miljkovic, B; Pokrajac, M; Timotijevic, I; Todorovic, D, 2011) |
| " A 3-week period of repeated, but unpredictable exposure to mild stressors induced a shift to the left of the dose-response curve for mCPP-induced penile erection." | 1.29 | Effects of repeated mild stress and two antidepressant treatments on the behavioral response to 5HT1C receptor activation in rats. ( Haefely, WE; Jenck, F; Martin, JR; Moreau, JL; Perrin, S, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (2.78) | 18.7374 |
| 1990's | 22 (61.11) | 18.2507 |
| 2000's | 4 (11.11) | 29.6817 |
| 2010's | 5 (13.89) | 24.3611 |
| 2020's | 4 (11.11) | 2.80 |
| Authors | Studies |
|---|---|
| Salgin-Goksen, U | 1 |
| Telli, G | 1 |
| Erikci, A | 1 |
| Dedecengiz, E | 1 |
| Tel, BC | 1 |
| Kaynak, FB | 1 |
| Yelekci, K | 1 |
| Ucar, G | 1 |
| Gokhan-Kelekci, N | 1 |
| Lafrenière, S | 1 |
| Blier, P | 1 |
| Schreiber, S | 1 |
| Keidan, L | 1 |
| Pick, CG | 1 |
| Grabowski, Ł | 1 |
| Jonsson, BH | 1 |
| Aswar, UM | 1 |
| Kalshetti, PP | 1 |
| Shelke, SM | 1 |
| Bhosale, SH | 1 |
| Bodhankar, SL | 1 |
| Wróbel, A | 1 |
| Serefko, A | 1 |
| Wlaź, P | 1 |
| Poleszak, E | 1 |
| Pekiner, FN | 1 |
| Gumru, B | 1 |
| Ozbayrak, S | 1 |
| Ignjatovic, AR | 1 |
| Miljkovic, B | 1 |
| Todorovic, D | 1 |
| Timotijevic, I | 1 |
| Pokrajac, M | 1 |
| Villarinho, JG | 1 |
| Fachinetto, R | 1 |
| de Vargas Pinheiro, F | 1 |
| da Silva Sant'Anna, G | 1 |
| Machado, P | 1 |
| Dombrowski, PA | 1 |
| da Cunha, C | 1 |
| de Almeida Cabrini, D | 1 |
| Pinto Martins, MA | 1 |
| Gauze Bonacorso, H | 1 |
| Zanatta, N | 1 |
| Antonello Rubin, M | 1 |
| Ferreira, J | 1 |
| Bonnet, U | 1 |
| Tatarczyńska, E | 1 |
| Kłodzińska, A | 1 |
| Stachowicz, K | 1 |
| Chojnacka-Wójcik, E | 1 |
| Koval'chuk, VV | 1 |
| Gleiter, C | 1 |
| Volz, HP | 1 |
| Ebert, D | 1 |
| Albert, R | 1 |
| May, A | 1 |
| Stosiek, I | 1 |
| Kaschka, W | 1 |
| Moreau, JL | 2 |
| Jenck, F | 2 |
| Martin, JR | 3 |
| Perrin, S | 1 |
| Haefely, WE | 1 |
| Mitchell, PB | 1 |
| Mitchell, MS | 1 |
| Scheen, AJ | 1 |
| Mortas, P | 1 |
| Haefely, W | 1 |
| Iakovlev, VA | 2 |
| Tanghe, A | 1 |
| Geerts, S | 1 |
| Van Dorpe, J | 1 |
| Brichard, B | 1 |
| Bruhwyler, J | 1 |
| Géczy, J | 1 |
| Amrein, R | 2 |
| Stabl, M | 1 |
| Henauer, S | 1 |
| Affolter, E | 1 |
| Jonkanski, I | 1 |
| Andriushchenko, AV | 1 |
| Kolesnikov, DB | 1 |
| Dubnitskaia, EB | 1 |
| Lotufo-Neto, F | 1 |
| Trivedi, M | 1 |
| Thase, ME | 1 |
| Meyers, BS | 1 |
| Delini-Stula, A | 1 |
| Baier, D | 1 |
| Kohnen, R | 1 |
| Laux, G | 1 |
| Philipp, M | 1 |
| Scholz, HJ | 1 |
| Montgomery, SA | 1 |
| Jansen Steur, EN | 1 |
| Ballering, LA | 1 |
| Cameron, AM | 1 |
| Allain, H | 1 |
| Lieury, A | 1 |
| Brunet-Bourgin, F | 1 |
| Mirabaud, C | 1 |
| Trebon, P | 1 |
| Le Coz, F | 1 |
| Gandon, JM | 1 |
| Stefanis, CN | 1 |
| Alevizos, B | 1 |
| Markianos, M | 1 |
| Hatzimanolis, J | 1 |
8 reviews available for moclobemide and Depression
| Article | Year |
|---|---|
Moclobemide: evolution, pharmacodynamic, and pharmacokinetic properties.
Topics: Animals; Antidepressive Agents; Anxiety; Cognition Disorders; Depression; Disease Models, Animal; Dr | 2002 |
The management of depression. Part 2. The place of the new antidepressants.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzamides; Depression; Drug Interactions; | 1994 |
Efficacy and tolerability of moclobemide in comparison with placebo, tricyclic antidepressants, and selective serotonin reuptake inhibitors in elderly depressed patients: a clinical overview.
Topics: Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzamides; Clinical Trials as Topic; | 1997 |
[A new generation of antidepressive agents -- monoamine oxidase inhibitors].
Topics: Aged; Antidepressive Agents; Benzamides; Clinical Trials as Topic; Depression; Humans; Moclobemide; | 1998 |
Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression.
Topics: Benzamides; Controlled Clinical Trials as Topic; Depression; Humans; Moclobemide; Monoamine Oxidase; | 1999 |
Depression and dementia: comorbidities, identification, and treatment.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Tricyclic; Benzamides; Citalopram; Clomipramine; Cog | 1998 |
Social phobia: diagnosis, severity and implications for treatment.
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Behavior Therapy; Benzamides; Benzodiazepines; Child | 1999 |
Moclobemide in patients with dementia and depression.
Topics: Animals; Benzamides; Cognition Disorders; Dementia; Depression; Humans; Moclobemide; Monoamine Oxida | 1999 |
8 trials available for moclobemide and Depression
| Article | Year |
|---|---|
Efficacy of moclobemide in burning mouth syndrome: a nonrandomized, open-label study.
Topics: Analysis of Variance; Antidepressive Agents; Anxiety; Burning Mouth Syndrome; Case-Control Studies; | 2008 |
[Pharmacologic correction of psycho-emotive disorders in the rehabilitation of patients after removal of brain tumors].
Topics: Adult; Alprazolam; Amitriptyline; Anti-Anxiety Agents; Antidepressive Agents; Anxiety; Brain Neoplas | 2007 |
[Moclobemide].
Topics: Antidepressive Agents; Benzamides; Depression; Depressive Disorder; Humans; Isoenzymes; Moclobemide; | 1995 |
Combined SSRI-RIMA treatment in refractory depression. Safety data and efficacy.
Topics: Adult; Benzamides; Depression; Drug Combinations; Female; Fluvoxamine; Humans; Male; Middle Aged; Mo | 1995 |
Double-blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase A inhibitors, pirlindole and moclobemide, in the treatment of depression.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antidepressive Agents; Benzamides; Carbazoles; Chi-Sq | 1997 |
Undesirable blood pressure changes under naturalistic treatment with moclobemide, a reversible MAO-A inhibitor--results of the drug utilization observation studies.
Topics: Adult; Aged; Benzamides; Blood Pressure; Cardiovascular Diseases; Comorbidity; Depression; Depressiv | 1999 |
Combined and selective monoamine oxidase inhibition in the treatment of depression in Parkinson's disease.
Topics: Adult; Aged; Benzamides; Cognition; Depression; Drug Combinations; Female; Humans; Male; Medical Rec | 1999 |
Antidepressants and cognition: comparative effects of moclobemide, viloxazine and maprotiline.
Topics: Adult; Antidepressive Agents; Arousal; Attention; Benzamides; Cognition; Depression; Double-Blind Me | 1992 |
20 other studies available for moclobemide and Depression
| Article | Year |
|---|---|
New 2-Pyrazoline and Hydrazone Derivatives as Potent and Selective Monoamine Oxidase A Inhibitors.
Topics: Animals; Antidepressive Agents; Depression; Hep G2 Cells; Humans; Hydrazones; Mice; Molecular Dockin | 2021 |
Remission from severe treatment-resistant depression with moclobemide: A case report.
Topics: Causality; Depression; Depressive Disorder, Treatment-Resistant; Humans; Moclobemide; Monoamine Oxid | 2023 |
Treatment-Resistant Depression (TRD): Is the Opioid System Involved?
Topics: Analgesics, Opioid; Animals; Antidepressive Agents; Depression; Dose-Response Relationship, Drug; Fl | 2023 |
Monoamine oxidase inhibitors (MAOI): pharmacology, metabolism and application in the treatment of depression
Topics: Depression; Humans; Moclobemide; Monoamine Oxidase; Monoamine Oxidase Inhibitors | 2021 |
Nicotinic Acid Long-Term Effectiveness in a Patient with Bipolar Type II Disorder: A Case of Vitamin Dependency.
Topics: Aged; Anticonvulsants; Antidepressive Agents; Bipolar Disorder; Depression; Dose-Response Relationsh | 2018 |
Effect of newly synthesized 1,2,4-triazino[5,6-b]indole-3-thione derivatives on olfactory bulbectomy induced depression in rats.
Topics: Acetamides; Acetanilides; Animals; Antidepressive Agents; Behavior, Animal; Depression; Disease Mode | 2012 |
The depressogenic-like effect of acute and chronic treatment with dexamethasone and its influence on the activity of antidepressant drugs in the forced swim test in adult mice.
Topics: Amitriptyline; Animals; Antidepressive Agents; Citalopram; Depression; Dexamethasone; Dose-Response | 2014 |
Evaluation of single-point sampling strategies for the estimation of moclobemide exposure in depressive patients.
Topics: Adult; Antidepressive Agents; Area Under Curve; Depression; Drug Administration Schedule; Drug Monit | 2011 |
Antidepressant-like effect of the novel MAO inhibitor 2-(3,4-dimethoxy-phenyl)-4,5-dihydro-1H-imidazole (2-DMPI) in mice.
Topics: Animals; Anisoles; Antidepressive Agents; Behavior, Animal; Biogenic Monoamines; Brain; Depression; | 2012 |
Effect of combined administration of 5-HT1A or 5-HT1B/1D receptor antagonists and antidepressants in the forced swimming test.
Topics: Adrenergic Uptake Inhibitors; Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Cita | 2004 |
Effects of repeated mild stress and two antidepressant treatments on the behavioral response to 5HT1C receptor activation in rats.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Benzamides; Depression; Dose-Response Relationship | 1993 |
[Drug of the month. Moclobemide (Aurorix)].
Topics: Benzamides; Depression; Humans; Moclobemide; Monoamine Oxidase Inhibitors | 1994 |
Effects of moclobemide, a new generation reversible Mao-A inhibitor, in a novel animal model of depression.
Topics: Animals; Benzamides; Depression; Disease Models, Animal; Male; Moclobemide; Monoamine Oxidase Inhibi | 1993 |
[The comparative efficacy of Aurorix and amitriptyline in treating depressions].
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzamides; Dep | 1997 |
[Aurorix--an antidepressant with a wide spectrum of action].
Topics: Antidepressive Agents; Anxiety; Benzamides; Contraindications; Depression; Dose-Response Relationshi | 1998 |
[Effectiveness of moclobemide in therapy-resistant depression].
Topics: Adult; Aged; Antidepressive Agents; Benzamides; Data Interpretation, Statistical; Depression; Drug R | 1998 |
[Various forms of risk factors of antidepressive agents for influencing sexual functions. Moclobemid is first choice for the therapy of sexually active patients with depression].
Topics: Antidepressive Agents; Anxiety; Benzamides; Depression; Depressive Disorder; Female; Humans; Male; M | 1999 |
If at first you do succeed.
Topics: 1-Naphthylamine; Antidepressive Agents; Benzamides; Depression; Fluoxetine; Half-Life; Humans; Moclo | 1991 |
The treatment of depression in the 1990s--a focus on moclobemide. A symposium. Lisbon, Portugal, 9-11 March 1989. Proceedings.
Topics: Antidepressive Agents; Benzamides; Depression; Humans; Moclobemide | 1990 |
Effect of moclobemide on clinical and neurochemical variables in depressed patients (preliminary findings).
Topics: Adult; Benzamides; Blood Platelets; Depression; Female; Growth Hormone; Humans; Hydroxyindoleacetic | 1988 |